Erschienen in:
23.02.2023 | ASO Author Reflections
ASO Author Reflections: A Perspective on Nonsentinel Axillary Lymph Node Status in Sentinel Lymph Node-Positive Early Breast Cancer After Primary Systemic Therapy and ALND-Predict
verfasst von:
Isaac Cebrecos, MD, Eduard Mension, MD, Maria Vidal, MD, PhD, Francesco Schettini, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2023
Einloggen, um Zugang zu erhalten
Excerpt
Sentinel lymph node biopsy (SLNB) was introduced as a staging method to lower lymphedema rates associated with axillary lymph node dissection (ALND) in patients with early breast cancer (EBC). Subsequent randomized prospective trials showed similar local/distant relapse and survival rates when avoiding ALDN in EBC patients, with up to two SLN affected with macrometastasis compared with ALND receivers. To note, the positive nonsentinel additional axillary lymph nodes (non-SLN
+) after ALND ranged from 13 to 33%, and most patients received adjuvant systemic treatment afterwards. However, the presence of residual disease deposits in SLN (SLN
+) after primary systemic treatment (PST) in baseline clinically node-negative (cN0) EBC patients might suggest poor response to neoadjuvant therapy, with uncertain prognostic implications.
1 Moreover, the exact rate of non-SLN
+ rates after ALND and associated predictive factors have never been described, with published reports only including heterogeneous groups of mixed baseline cN0 and node-positive (cN
+) cohorts.
2 …
